Identification and development of a 1st in class naturally-derived protein that drives mucosal healing and is orally delivered by an engineered cellular therapy targeting the gastro-intestinal tract

SUMMARY

SG-2-0776 is a novel protein that demonstrated improvement in barrier function and inhibits fibrinogen marks. SG-2-0776 targets PAI-1 resulting in higher IPH activity,

SG-2-0776 plays the potential to be a first-in-class treatment in IBD for patients with inadequate response to the standard of care.

ACKNOWLEDGMENTS

None.

REFERENCES


